Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
Drs. Atkins and Choueiri discuss the latest advances in the use of immunotherapy in patients with mRCC. This activity is intended for oncologists, urologists and nephrologists. The goal of this activity is to review the latest advances in the use of checkpoint inhibitors in patients with metastatic renal cell carcinoma (mRCC).
Approximate Time to Complete: 45 minutes
Course Available Beginning: May 30, 2017
Developed through a partnership between SITC and Medscape.
 |
 |
- Have increased knowledge regarding the latest data on the use of immune checkpoint inhibition in the management of patients with mRCC
- Have increased knowledge regarding the identification of appropriate candidates for the use of an immune checkpoint inhibitor, based on tumor factors, patient factors, and adverse events